Visitors Now:
Total Visits:
Total Stories:
Profile image
By American Anglican Council (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Biotech Clusters

Thursday, August 23, 2012 8:21
% of readers think this story is Fact. Add your two cents.

(Before It's News)

How important is it to have a “anchor” company in a regional bio/pharma cluster? How do you get a thriving cluster of biotech companies, anyway? There are a lot of cities that would like the answers to these questions, not that anyone has them (although there are consultants who will be glad to convince you otherwise).

Luke Timmerman has thoughts on the subject here, pointing out that some of the more well-known biotech hubs have been losing some of their marquee names to takeovers and the like. This has to have an effect, and the question is just how big (or bad) it’ll be.

Other companies, in some places, might be able to step up and fill the void, but not always. If there isn’t a robust culture in an area (or not yet), then taking out the main company that’s driving things might bring the whole process to a halt. If, in fact, it is a process – and that takes us back to the whole question of how these clusters get started in the first place. The biggest and most impressive share some common features (well–known research universities in the area, to pick the most obvious), but what seem to be very similar features in other locations can fail to produce similar results.

Many are the cities that have tried to grow their own Silicon Valleys and Boston/Cambridges. Overall, I’m skeptical of attempts to purposefully induce these sorts of things, and that goes both for R&D clusters as well as the various city-planning attempts to bring in young creative-class types. At best, these seem to me to be likely to missing some key variables, and at worst, it’s reminiscent of South Pacific cargo cults. (“If we make this look like a happening city, then that’s what it’ll be!”) It’s not that I don’t think more research hot spots would be a bad thing, of course – just the opposite. It’s just that I don’t know how you achieve that result.

Derek Lowe is a medicinal chemist with over 20 years experience in the drug industry. He blogs daily on science and drug discovery at In The Pipeline



Source:

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.